Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L8VA
|
|||
| Former ID |
DIB004146
|
|||
| Drug Name |
CSL-112
|
|||
| Synonyms |
Reconstituted HDL (acute coronary syndrome), CSL
Click to Show/Hide
|
|||
| Indication | Arteriosclerosis [ICD-11: BD40; ICD-10: I70] | Phase 2 | [1] | |
| Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99, E78; ICD-9: 390-459] | Phase 2 | [2] | ||
| Company |
Csl
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02108262) A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis. 2014 Jan;232(1):110-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.